ARCELLX-ACLX-001-DDBCMA
Phase I
OPEN TO ACCRUAL
Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma, Including Long-Term Safety Follow-Up
FATE-FT576-101-MM
Phase I
OPEN TO ACCRUAL
A Phase I Study of FT576 as Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma
JNJ-MY4002-CARTINUE-LTFU
Phase IV
OPEN TO ACCRUAL
Long-Term Follow-Up Study for Participants Previously Treated with Ciltacabtagene Autoleucel